Proceedings of the Food and Drug Administration's public workshop on new red blood cell product regulatory science 2016

E-ISSN： 1537-2995|58|1|255-266

ISSN： 0041-1132

Source： TRANSFUSION, Vol.58, Iss.1, 2018-01, pp. : 255-266

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

US Food and Drug Administration regulatory oversight of laboratory‐developed tests: Commentary on the draft guidance

CANCER CYTOPATHOLOGY, Vol. 123, Iss. 10, 2015-10 ,pp. : 573-575

John Wiley & Sons Inc

Access to resources Recommend Favorite

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

HEPATOLOGY, Vol. 61, Iss. 4, 2015-04 ,pp. : 1392-1405

John Wiley & Sons Inc

Access to resources Recommend Favorite

Red Blood Cell Clearance in Inflammation

Transfusion Medicine and Hemotherapy, Vol. 39, Iss. 5, 2012-09 ,pp. : 353-360

Karger

Access to resources Recommend Favorite

The red blood cell in vascular occlusion

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 5-6, 2003-08 ,pp. : 263-268

Karger

Access to resources Recommend Favorite

The evaluation of a new apheresis device for automated red blood cell exchange procedures in patients with sickle cell disease

TRANSFUSION, Vol. 55, Iss. 4, 2015-04 ,pp. : 775-781

John Wiley & Sons Inc

Access to resources Recommend Favorite